Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
5'-Nucleotidase, cytosolic IIIB (cN-IIIB; NT5C3B) is an intracellular enzyme catalyzing the hydrolytic dephosphorylation of nucleoside 5'-monophosphates, with a distinctive specificity for 7-methylguanosine monophosphate (m^7^GMP)[2][3]. This activity is thought to protect cells from inappropriate salvage and reincorporation of methylated nucleotides, thus maintaining nucleotide pool integrity[2]. Structurally, cN-IIIB belongs to the haloacid dehalogenase (HAD) superfamily, with a core Rossmannoid α/β domain and a smaller CAP domain that contributes to substrate specificity and active-site lid function[1][3]. While other 5'-nucleotidases (e.g., NT5C3A/cN-IIIA) have established clinical and disease relevance, no direct disease associations, drug inhibitors, or biomarker roles for NT5C3B are reported in the literature as of now[2][3]. The enzyme is predicted to localize in the cytosol and cytoplasm and plays a supporting role in nucleotide and RNA metabolism[2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 5'-Nucleotidase, cytosolic IIIB (cN-IIIB).